AYTU BioPharma
AYTU
33 hedge funds and large institutions have $6.73M invested in AYTU BioPharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
3% more funds holding
Funds holding: 32 → 33 (+1)
1.83% more ownership
Funds ownership: 38.06% → 39.88% (+1.8%)
10% less capital invested
Capital invested by funds: $7.45M → $6.73M (-$716K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$630K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$579K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$183K |
| 4 |
PAP
Persistent Asset Partners
Hong Kong
|
+$144K |
| 5 |
Two Sigma Advisers
New York
|
+$92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWM
Kanen Wealth Management
Coconut Creek,
Florida
|
-$1.25M |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$82.7K |
| 3 |
HF
HRT Financial
New York
|
-$43K |
| 4 |
AIC
AWM Investment Company
New York
|
-$693 |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$344 |
AYTU Hedge Fund Activity: Q3 2025 in Review
33 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2025, worth a combined $6.73M — down 9.6% from $7.45M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AYTU positions and 4 closed out — a net gain of 2 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Diadema Partners, opening a new position worth an estimated $630K. The largest seller was Kanen Wealth Management, exiting entirely with an estimated $1.25M sold.
- 33 institutional investors held AYTU BioPharma (AYTU) as of Q3 2025, up from 32 in Q2 2025.
- Funds reported $6.73M of AYTU BioPharma stock for Q3 2025, down 9.6% quarter-over-quarter.
- 6 funds opened new AYTU BioPharma positions in Q3 2025 and 4 closed out, a net change of +2 holders.
- The largest AYTU BioPharma buyer in Q3 2025 was Diadema Partners, an estimated $630K added.
- The largest AYTU BioPharma seller in Q3 2025 was Kanen Wealth Management, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2025.